In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242216445 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Bright C Uzuegbunam und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Technical University of Munich, 81675 Munich, Germany. Hauptthemen laut MEDLINE: Synucleinopathies, Neurodegenerative Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Parkinsonfonds Deutschland, the Michael J. Fox Foundation, the Rainwater Charitable Foundation.
Abstract (Originalsprache)
The α-synucleinopathies are a group of neurodegenerative diseases characterized by the deposition of α-synuclein aggregates (α-syn) in the brain. Currently, there is no suitable tracer to enable a definitive early diagnosis of these diseases. We reported candidates based on 4,4′-disarylbisthiazole (DABTA) scaffold with a high affinity towards α-syn and excellent selectivity over Aβ and tau fibrils. Based on prior in silico studies, a focused library of 23 halogen-containing and O-methylated DABTAs was prepared. The DABTAs were synthesized via a modified two-step Hantzsch thiazole synthesis, characterized, and used in competitive binding assays against [3H]PiB and [3H]DCVJ. The DABTAs were obtained with an overall chemical yield of 15–71%, and showed a calculated lipophilicity of 2.5–5.7. The ligands demonstrated an excellent affinity to α-syn with both [3H]PiB and [3H]DCVJ: Ki 0.1–4.9 nM and up to 20–3900-fold selectivity over Aβ and tau fibrils. It could be concluded that in silico simulation is useful for the rational design of a new generation of DABTAs. Further investigation of the leads in the next step is encouraged: radiolabeling of the ligands with radioisotopes such as fluorine-18 or carbon-11 for in vivo, ex vivo, and translational research and for further in vitro experiments on human-derived protein aggregates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Technical University of Munich, 81675 Munich, Germany.
- Department of Physics and Astronomy, Uppsala University, 751 20 Uppsala, Sweden.
- Department of Clinical Neuroscience, Karolinska Institute, 171 76 Stockholm, Sweden.
- Department of Nuclear Medicine, Philipps University of Marburg, 35043 Marburg, Germany.
ORCID-Profile: Wojciech Paslawski, Per Svenningsson, Hans Ågren, Behrooz Hooshyar Yousefi
Förderung
- Parkinsonfonds Deutschland
- the Michael J. Fox Foundation
- the Rainwater Charitable Foundation
- the National Academic Infrastructure for Super-computing in Sweden (NAISS) at the National Supercomputer Centre at Linköping University (Sweden)
- the Swedish Research Council
Zitieren
APA
Uzuegbunam, B. C., Li, J., Paslawski, W., Weber, W., Svenningsson, P., Ågren, H., & Hooshyar Yousefi, B. (2023). In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242216445
Vancouver
Uzuegbunam BC, Li J, Paslawski W, Weber W, Svenningsson P, Ågren H, et al. In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242216445
BibTeX
@article{Uzuegbunam2023,
author = {Uzuegbunam, Bright C and Li, Junhao and Paslawski, Wojciech and Weber, Wolfgang and Svenningsson, Per and Ågren, Hans and Hooshyar Yousefi, Behrooz},
title = {In Silico and In Vitro Study towards the Rational Design of 4,4′-Disarylbisthiazoles as a Selective α-Synucleinopathy Biomarker},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242216445}
}
EUVIMED